NASDAQ:OMCL - Omnicell Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $129.25
Forecasted Upside: -12.05 %
Number of Analysts: 9
Breakdown:
0 Sell Ratings
3 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$146.96 As of 06/21/2021 01:00 AM ET

▲ +3.28 (2.28%)

1 month | 3 months | 12 months

Get New Omnicell Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for OMCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMCL

^$129.25

▼ -12.05% Downside Potential

This price target is based on 9 analysts offering 12 month price targets for Omnicell in the last 3 months. The average price target is $129.25, with a high forecast of $165.00 and a low forecast of $84.00. The average price target represents a -12.05% upside from the last price of $146.96.

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Omnicell. This rating has held steady since January 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/9/2021	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$146.00	Low
5/24/2021	BTIG Research	Initiated Coverage	Buy	$165.00	Low
4/30/2021	Benchmark	Boost Price Target	Buy	$155.00 ➝ $160.00	Low
4/30/2021	Piper Sandler	Boost Price Target	Overweight	$147.00 ➝ $152.00	Medium
3/22/2021	Benchmark	Boost Price Target	Buy	$140.00 ➝ $155.00	Low
2/2/2021	Piper Sandler	Upgrade	Neutral ➝ Overweight	$86.00 ➝ $147.00	N/A
1/20/2021	Benchmark	Boost Price Target	Buy	$125.00 ➝ $140.00	Low
1/14/2021	Craig Hallum	Boost Price Target	Buy	$100.00 ➝ $142.00	Low
12/9/2020	Benchmark	Boost Price Target	Buy	$100.00 ➝ $125.00	High
12/8/2020	Berenberg Bank	Initiated Coverage	Buy		High
12/3/2020	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$95.00	High
10/28/2020	Craig Hallum	Boost Price Target	Buy	$85.00 ➝ $100.00	High
10/28/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$74.00 ➝ $84.00	Low
10/28/2020	Benchmark	Boost Price Target	Buy	$82.00 ➝ $100.00	Low
10/28/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$90.00 ➝ $95.00	Low
10/28/2020	Piper Sandler	Boost Price Target	Neutral	$70.00 ➝ $86.00	Low
7/29/2020	Craig Hallum	Lower Price Target	Buy	$102.00 ➝ $85.00	Medium
7/29/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$85.00 ➝ $90.00	High
7/29/2020	Piper Sandler	Lower Price Target	Neutral	$76.00 ➝ $70.00	High
7/6/2020	Stephens	Initiated Coverage	Overweight	$90.00	Medium
5/8/2020	Benchmark	Lower Price Target	Buy	$96.00 ➝ $82.00	High
5/8/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$95.00 ➝ $85.00	High
5/8/2020	Piper Sandler	Lower Price Target	Neutral	$88.00 ➝ $76.00	High
2/7/2020	Piper Sandler	Reiterated Rating	Hold	$88.00	Medium
2/7/2020	Dougherty & Co	Boost Price Target	Buy	$92.00 ➝ $100.00	High
1/8/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$80.00 ➝ $85.00	Low
12/11/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$91.00 ➝ $95.00	Low
11/21/2019	Dougherty & Co	Boost Price Target	Buy	$90.00 ➝ $92.00	Medium
10/25/2019	Sidoti	Set Price Target	Hold	$82.00	N/A
7/26/2019	Craig Hallum	Upgrade	Hold ➝ Buy	$85.00	Low
4/26/2019	Benchmark	Boost Price Target	Buy	$82.00 ➝ $90.00	Low
4/26/2019	Craig Hallum	Downgrade	Buy ➝ Hold	$84.00	Low
3/7/2019	Dougherty & Co	Boost Price Target	Buy	$78.00 ➝ $90.00	Low
2/8/2019	Piper Jaffray Companies	Reiterated Rating	Neutral	$70.00	High
12/7/2018	Oppenheimer	Boost Price Target	Outperform	$86.00	Low
12/6/2018	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$70.00 ➝ $80.00	Low
10/29/2018	Wells Fargo & Company	Boost Price Target	Market Perform ➝ Market Perform	$59.00 ➝ $61.00	Medium
10/26/2018	Oppenheimer	Boost Price Target	Outperform ➝ Outperform	$71.00 ➝ $73.00	N/A
10/26/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $70.00	High
10/5/2018	Benchmark	Boost Price Target	Buy	$66.00 ➝ $79.00	Low
9/17/2018	Craig Hallum	Boost Price Target	Buy	$65.00 ➝ $80.00	Medium
7/27/2018	Piper Jaffray Companies	Boost Price Target	Neutral ➝ Neutral	$44.00 ➝ $55.00	High
7/27/2018	Craig Hallum	Upgrade	Hold ➝ Buy	$33.00	High
7/26/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$63.00	High
6/29/2018	Benchmark	Initiated Coverage	Buy ➝ Buy	$63.00	Low
4/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$63.00	Medium
2/2/2018	Piper Jaffray Companies	Boost Price Target	Neutral ➝ Neutral	$38.00 ➝ $44.00	High
2/2/2018	Craig Hallum	Downgrade	Buy ➝ Hold		High
2/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$63.00	High
1/29/2018	Oppenheimer	Reiterated Rating	Buy	$55.00	Medium
12/13/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00	Medium
12/5/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00	Low
12/5/2017	Oppenheimer	Reiterated Rating	Buy	$55.00	Low
10/30/2017	Craig Hallum	Reiterated Rating	Buy	$52.00 ➝ $62.00	N/A
10/27/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$58.00	N/A
10/19/2017	Oppenheimer	Reiterated Rating	Buy	$55.00	N/A
9/5/2017	Benchmark	Boost Price Target	Buy ➝ Buy	$55.00 ➝ $67.00	Medium
7/30/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$40.00	Medium
7/28/2017	Dougherty & Co	Boost Price Target	Buy	$45.00 ➝ $49.00	High
7/28/2017	Craig Hallum	Boost Price Target	Buy	$46.00 ➝ $52.00	High
7/25/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$47.00	Medium
6/13/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$43.00 ➝ $47.00	Low
4/26/2017	CIBC	Boost Price Target	Outperform	$43.00 ➝ $53.00	Low
4/25/2017	Oppenheimer	Reiterated Rating	Outperform	$43.00 ➝ $53.00	High
4/21/2017	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$40.00	High
3/6/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$38.00 ➝ $43.00	N/A
1/19/2017	Dougherty & Co	Initiated Coverage	Buy	$44.00	N/A
1/5/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$40.00	N/A
12/6/2016	Benchmark	Boost Price Target	Buy	$39.00 ➝ $55.00	N/A
10/27/2016	Oppenheimer	Set Price Target	Buy	$46.00	N/A
9/13/2016	Oppenheimer	Reiterated Rating	Outperform	$46.00	N/A
9/8/2016	Sidoti	Downgrade	Buy ➝ Neutral	$43.00	N/A
7/29/2016	(FBRC)	Boost Price Target	Outperform	$40.00 ➝ $41.00	N/A
7/7/2016	(FBRC)	Boost Price Target	Outperform	$35.00 ➝ $40.00	N/A

(Data available from 6/22/2016 forward)

Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Today's Range

Now: $146.96

$143.71

$148.19

50 Day Range

MA: $138.54

$129.91

$146.96

52 Week Range

Now: $146.96

$62.24

$148.19

Volume

265,650 shs

Average Volume

351,558 shs

Market Capitalization

$6.35 billion

P/E Ratio

190.86

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Omnicell?

The following Wall Street sell-side analysts have issued stock ratings on Omnicell in the last year: Benchmark Co., Berenberg Bank, BTIG Research, Cantor Fitzgerald, Craig Hallum, JPMorgan Chase & Co., Piper Sandler, Stephens, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for OMCL.

What is the current price target for Omnicell?

8 Wall Street analysts have set twelve-month price targets for Omnicell in the last year. Their average twelve-month price target is $129.25, suggesting a possible downside of 12.1%. BTIG Research has the highest price target set, predicting OMCL will reach $165.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $84.00 for Omnicell in the next year.
View the latest price targets for OMCL.

What is the current consensus analyst rating for Omnicell?

Omnicell currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OMCL will outperform the market and that investors should add to their positions of Omnicell.
View the latest ratings for OMCL.

What other companies compete with Omnicell?

Other companies that are similar to Omnicell include Cerner, Allscripts Healthcare Solutions, Cortexyme, Vocera Communications, HealthStream, Computer Programs and Systems, Athena Technology Acquisition and Mirage Energy.

How do I contact Omnicell's investor relations team?

Omnicell's physical mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company's listed phone number is 650-251-6100 and its investor relations email address is [email protected] The official website for Omnicell is www.omnicell.com.